Fosun Pharma Subsidiary Launches Co-Developed Biochemical Reagent with Siemens Healthineers
CompanyDeals

Fosun Pharma Subsidiary Launches Co-Developed Biochemical Reagent with Siemens Healthineers

CSPC Pharma Receives NMPA Approval for Hydroxocobalamine in Pediatric MMA Treatment
CompanyDrug

CSPC Pharma Receives NMPA Approval for Hydroxocobalamine in Pediatric MMA Treatment

Kanion Pharma and Space Peptides Submit IND for AI-Enabled CCR8 Peptide Inhibitor KYS2301
CompanyDrug

Kanion Pharma and Space Peptides Submit IND for AI-Enabled CCR8 Peptide Inhibitor KYS2301

CR Medical Holdings Partners with Shanghai Haohai Bio in Medical Aesthetics Sector
CompanyDeals

CR Medical Holdings Partners with Shanghai Haohai Bio in Medical Aesthetics Sector

Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China
CompanyDeals

Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China

AstraZeneca CEO Soriot Explores US Stock Listing Move, Potentially Impacting London Exchange
CompanyDeals

AstraZeneca CEO Soriot Explores US Stock Listing Move, Potentially Impacting London Exchange

Shanghai Henlius Biotech Earns GMP Certification for Prolia/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11
CompanyDrug

Shanghai Henlius Biotech Earns GMP Certification for Prolia/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11

Dizal’s Sunvozertinib Receives FDA Accelerated Approval for EGFR Exon20ins NSCLC
CompanyDrug

Dizal’s Sunvozertinib Receives FDA Accelerated Approval for EGFR Exon20ins NSCLC

Servier’s Voranigo Approved for IDH-Mutant Diffuse Glioma in Beijing
CompanyDrug

Servier’s Voranigo Approved for IDH-Mutant Diffuse Glioma in Beijing

Sichuan Biokin's Iza-bren Meets Primary Endpoint in Phase III NPC Trial
CompanyDrug

Sichuan Biokin’s Iza-bren Meets Primary Endpoint in Phase III NPC Trial

Genrix Bio Receives NMPA Clearance for GR1803 in Relapsed/Refractory Multiple Myeloma
CompanyDrug

Genrix Bio Receives NMPA Clearance for GR1803 in Relapsed/Refractory Multiple Myeloma

Simcere Pharma's Suvemcitug Approved by China's NMPA for Platinum-Resistant Ovarian Cancer
CompanyDrug

Simcere Pharma’s Suvemcitug Approved by China’s NMPA for Platinum-Resistant Ovarian Cancer